JL
Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
johnson-and-johnson-innovative-medicineTherapeutic Areas
johnson-and-johnson-innovative-medicine Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ICOTYDE (icotrokinra) | Moderate-to-Severe Plaque Psoriasis | Approved |
| TECVAYLI + DARZALEX FASPRO | Relapsed/Refractory Multiple Myeloma | Approved |
| Nipocalimab | Systemic Lupus Erythematosus (SLE) | Phase 3 |
| Undisclosed Programs | Alzheimer's Disease | Pipeline |